Purple Biotech Ltd. (NASDAQ:PPBT) stock is surging on Wednesday following a favorable U.S. patent update.
The U.S. Patent and Trademark Office granted the biotechnology company a Notice of Allowance regarding a crucial patent application that covers its tri-specific antibody constructs and their specific methods of application.
Expanding Intellectual Property Defenses
The newly authorized patent substantially broadens the intellectual property portfolio safeguarding Purple Biotech’s proprietary CAPTN-3 platform.
The advanced technology focuses on creating conditionally activated multispecific antibodies for therapeutic applications.
Specifically, the regulatory allowance fortifies the legal protection surrounding the modular architecture that serves as the foundation for the CAPTN-3 platform.
The underlying framework enables scientists to efficiently generate versatile tri-specific antibodies.
It achieves this by allowing the exchange of tumor-associated antigen (TAA) binding domains and various other functional extensions while maintaining a consistent structural backbone.
Accelerating Cancer Treatment Development
By leveraging this inherent structural flexibility, the company intends to rapidly accelerate the development timeline for new therapeutic candidates targeting a wide array of cancer indications.
The specific claims allowed by the patent office encompass tri-specific antibody constructs that incorporate dual TAA binders alongside other distinguishing features of the CAPTN-3 system.
In April, the cancer immunotherapy company shared new preclinical data supporting the clinical potential of IM1240, the company’s lead CAPTN-3 tri-specific antibody.
The data demonstrated potent anti-tumor activity for IM1240 across multiple treatment-resistant patient-derived tumor samples.
The company aims to start human trials for IM1240 in 2027.
PPBT Stock Price Activity: Purple Biotech shares were up 22.89% at $2.03 during premarket trading on Wednesday, according to Benzinga Pro data.
Photo via Shutterstock
